Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES2 | Q9H7Z7 | 5/20 | 0.80 |
| ▸ | PDK1 | Q15118 | 7/20 | 0.56 |
| ▸ | PDK2 | Q15119 | 7/20 | 0.56 |
| ▸ | PDK3 | Q15120 | 7/20 | 0.56 |
| ▸ | PDK4 | Q16654 | 7/20 | 0.56 |
| ▸ | ABCC9 | O60706 | 6/20 | 0.53 |
| ▸ | ABCC8 | Q09428 | 6/20 | 0.53 |
| ▸ | KCNJ11 | Q14654 | 6/20 | 0.53 |
| ▸ | KCNJ8 | Q15842 | 6/20 | 0.53 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5736422 | 0.90 | PTGES2 (0.80) | PTGES2PDK1PDK2PDK3PDK4 | |
| SCHEMBL3785994 | 0.89 | PTGES2 (1.00) | PTGES2PDK1PDK2PDK3PDK4 | |
| SCHEMBL5737767 | 0.80 | PTGES2 (0.66) | PTGES2PDK1PDK2PDK3PDK4 | |
| SCHEMBL4608257 | 0.79 | ABCC9 (0.72) | PDK1PDK2PDK3PDK4ABCC9 | |
| SCHEMBL4608254 | 0.79 | ABCC9 (0.72) | PDK1PDK2PDK3PDK4ABCC9 | |
| SCHEMBL5737269 | 0.78 | PDK1 (0.68) | PTGES2PDK1PDK2PDK3PDK4 | |
| SCHEMBL6570953 | 0.78 | ABCC9 (0.64) | PTGES2PDK1PDK2PDK3PDK4 | |
| SCHEMBL5737699 | 0.78 | PTGES2 (0.81) | PTGES2PDK1PDK2PDK3PDK4 | |
| SCHEMBL5735151 | 0.77 | ALDH1A1 (0.50) | PTGES2PDK1PDK2PDK3PDK4 | |
| SCHEMBL6569524 | 0.76 | NR1H2 (0.53) | PTGES2PDK1PDK2PDK3PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331321-A1 | Bis-(Sulfonylamino) derivatives for use in therapy | ASTRAZENECA AB (SE) | 2010-12-30 | — | — | US | disclosed |
| US-20090163586-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 205 | ASTRAZENECA AB (SE) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163586-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 205 | PTGER1, SULT2A1, SULT1E1 | PTGES2 30/4885PDK1 1101/4885PDK2 1367/4885 |
| US-20100331321-A1 | Bis-(Sulfonylamino) derivatives for use in therapy | PTGER1, SULT2A1, SULT1E1 | PTGES2 25/4885PDK1 838/4885PDK2 954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.